-
Ferring announces new million euro educational initiative with International Federation of Fertility Societies (IFFS) and Elsevier
in PRESS RELEASE 2012 onWorld leader in fertility treatments, Ferring Pharmaceuticals, announced today at the 2012 Updates in Infertility Treatment (UIT) meeting that…
-
Acquisition of Cytokine
in TIMELINES onAcquisition of Cytokine PharmaSciences Inc. (CPSI) and its subsidiary, Controlled Therapeutics Scotland (CTS). The new entity called Ferring Controlled Therapeutics…
0 -
Similar remission results shown between once-daily 4g dose and twice-daily 2g doses of mesalazine (PENTASA®) in active ulcerative colitis
in PRESS RELEASE 2011 onResults of a new study 1 presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate…
-
Ferring Pharmaceuticals acquires Cytokine PharmaSciences Inc.
in PRESS RELEASE 2011 onFerring Pharmaceuticals (Ferring) announced today that it has completed the purchase of Cytokine PharmaSciences Inc. (CPSI) and its…
-
The untold impact of childhood bedwetting in later life
in PRESS RELEASE 2011 onNew data, presented today at the International Continence Society (ICS) congress in Glasgow1, suggest that bedwetting…
-
New research reveals night-time toilet trips are not a trivial problem
in PRESS RELEASE 2011 onNew data, presented at the International Continence Society (ICS) Congress, highlight the significant detrimental impact of nocturia…
-
New data demonstrating long-term benefits of FIRMAGON® (degarelix) for advanced hormone-dependant prostate cancer published in The Journal of Urology
in PRESS RELEASE 2011 onNew data, published in the September issue of The Journal of Urology, showed that long-term use of FIRMAGON®…
-
MEGASET Study demonstrated effectiveness and tolerability of MENOPUR® after ICSI in GnRH antagonist cycles
in PRESS RELEASE 2011 onNew data1, presented today at the European Society of Human Reproduction and Embryology (ESHRE) meeting, demonstrated the efficacy…
-
Ongoing extension study results provide further evidence for first-line use of FIRMAGON® (degarelix) in advanced prostate cancer
in PRESS RELEASE 2011 onRecent data from the ongoing five-year FIRMAGON® (degarelix) extension study (CS21a) has demonstrated the long term efficacy and tolerability of…
-
SMC Announces Acceptance of Degarelix (FIRMAGON®▼) for use within NHS Scotland
in PRESS RELEASE 2011 onToday’s decision by the Scottish Medicines Consortium (SMC) (www.scottishmedicines.org.uk) to accept the use of FIRMAGON…
Author archive for pulse
Articles by: pulse
